-
Spark Therapeutics To Merge With Roche
Post on 2/25/19
-
Better Buy: Amgen vs. Celgene
Post on 2/25/19
-
What Pharma Investors Need to Know About Pfizer's Latest Disaster
Post on 2/22/19
-
Geneos Therapeutics Secures $10.5 Million in Series A
Post on 2/21/19
-
Anixa Biosciences Extends Collaborative Research Agreement with The Wistar Institute
Post on 2/21/19
-
Merck to Acquire Immune Design for $300M
Post on 2/21/19
-
Better Buy: Pfizer vs. Eli Lilly
Post on 2/20/19
-
Quest Diagnostics Partners With Houston Healthcare
Post on 2/20/19
-
Johnson & Johnson Looks Undervalued: Time To Buy?
Post on 2/20/19
-
Pfizer's Forgotten Cancer Pill Is About to Become Its Next Blockbuster
Post on 2/20/19
-
Teva Is Cheap And It Can Get Cheaper
Post on 2/20/19
-
Pernix Therapeutics Holdings Enters into Asset Purchase Agreement with Certain Funds Managed by Highbridge Capital Management
Post on 2/19/19
-
Recro Pharma Reports Financial Results for the Fourth Quarter and Year End 2018
Post on 2/19/19
-
Pfizer In NASH: Left Behind And The Desperate Refocus
Post on 2/19/19
-
Better Buy: Celgene vs. Gilead Sciences
Post on 2/19/19
-
Better Buy: Intercept Pharmaceuticals vs. Madrigal Pharmaceuticals
Post on 2/19/19
-
Cambrooke Therapeutics and Trovita Health Science Announce Strategic Alliance
Post on 2/18/19
-
Outlook Therapeutics Provides Business Update
Post on 2/18/19
-
Tabula Rasa HealthCare Closes Offering of 1.75% Convertible Notes
Post on 2/18/19
-
Did Johnson & Johnson Just Spit in Alphabet's Face?
Post on 2/15/19
-
Teva Pharmaceutical Industries (TEVA) Q4 2018 Earnings Conference Call Transcript
Post on 2/15/19
-
Glenmark to Spin Off its Innovation Business into a New Company in the US
Post on 2/14/19
-
FDA Clears Next SIG Medical AdvantageRib System
Post on 2/14/19
-
Inovio Pharmaceuticals Prices $65.0 Million Convertible Senior Notes Offering
Post on 2/14/19
-
Johnson & Johnson: Regulatory Headwinds Compromise Half Of Future Revenue Streams
Post on 2/14/19